MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications

Bravo-Vázquez, Luis Alberto; Frías-Reid, Natalia; Ramos-Delgado, Ana Gabriela; Osorio-Pérez, Sofía Madeline; Zlotnik-Chávez, Hania Ruth; Pathak, Surajit; Banerjee, Antara; Bandyopadhyay, Anindya; Duttaroy, Asim K.; Paul, Sujay

doi:10.1016/j.tranon.2022.101579

Cited by 20 publications

(10 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lncRNA1 which delays senescence 33 . Certain lncRNAs are biomarkers for age-associated diseases and could provide more readily accessible drug targets than proteins 19,34,35 . Hence, lncRNAs are emerging as important, yet poorly characterized aging factors, presenting a promising research frontier.…”

Section: Introductionmentioning

confidence: 99%

Aging-associated long non-coding RNA boosts longevity and reduces the ribosome content of non-dividing fission yeast cells

Anver,

Sumit,

Sun

et al. 2024

Preprint

View full text Add to dashboard Cite

Genomes produce widespread long non-coding RNAs (lncRNAs) of largely unknown functions. We characterize aal1 (aging-associated lncRNA) which is induced in quiescent cells of fission yeast. Deletion of aal1 shortens the chronological lifespan of non-dividing cells, while ectopic overexpression of aal1 prolongs their lifespan, indicating that this lncRNA acts in trans. The overexpression of aal1 leads to the repression of ribosomal protein genes and inhibition of cell growth, and aal1 genetically interacts with coding genes functioning in protein translation. The aal1 RNA localizes to the cytoplasm and associates with ribosomes. Notably, aal1 deletion or overexpression is sufficient to increase or decrease the cellular ribosome content. The rpl1901 mRNA, encoding a ribosomal protein, is a binding target of aal1. The levels of rpl1901 are reduced ~2-fold by aal1, which is critical and sufficient to extend the lifespan. Remarkably, the expression of aal1 lncRNA in Drosophila triggers an extension of fly lifespan. We propose that aal1 reduces the ribosome content by decreasing the levels of Rpl1901, thus attenuating protein translation and promoting longevity. Although the aal1 lncRNA itself is not conserved, its effect in flies raises the possibility that animals feature related mechanisms that modulate aging, based on the conserved translational machinery.

show abstract

Section: Introductionmentioning

confidence: 99%

Aging-associated long non-coding RNA boosts longevity and reduces the ribosome content of non-dividing fission yeast cells

Anver,

Sumit,

Sun

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Since miRNAs are involved in several biological processes, their dysregulation gives rise to various health disorders, including cancer (Paul et al, 2020a;Paul et al, 2020b;Paul et al, 2020c;Paul et al, 2021a;Paul et al, 2021b;Bravo-Vázquez et al, 2022;Paul et al, 2022;Ruiz-Manriquez et al, 2022;Bravo-Vázquez et al, 2023a;Bravo-Vázquez et al, 2023b). In fact, have been identified as oncogenes (oncomiRs) (Fu et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Bravo-Vázquez,

Méndez-García,

Rodríguez

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short (18–25 nt), non-coding, widely conserved RNA molecules responsible for regulating gene expression via sequence-specific post-transcriptional mechanisms. Since the human miRNA transcriptome regulates the expression of a number of tumor suppressors and oncogenes, its dysregulation is associated with the clinical onset of different types of cancer. Despite the fact that numerous therapeutic approaches have been designed in recent years to treat cancer, the complexity of the disease manifested by each patient has prevented the development of a highly effective disease management strategy. However, over the past decade, artificial miRNAs (i.e., anti-miRNAs and miRNA mimics) have shown promising results against various cancer types; nevertheless, their targeted delivery could be challenging. Notably, numerous reports have shown that nanotechnology-based delivery of miRNAs can greatly contribute to hindering cancer initiation and development processes, representing an innovative disease-modifying strategy against cancer. Hence, in this review, we evaluate recently developed nanotechnology-based miRNA drug delivery systems for cancer therapeutics and discuss the potential challenges and future directions, such as the promising use of plant-made nanoparticles, phytochemical-mediated modulation of miRNAs, and nanozymes.

show abstract

“…Nearly 60% of the human genome is regulated by miRNAs, suggesting that they are involved in almost all essential cellular functions [ 30 , 31 ]. Mounting evidence has demonstrated that miRNA expression is frequently altered in complex pathophysiologies, including cancer [ 32 , 33 , 34 ]. Many studies have also confirmed the crucial role of miRNAs in various cancer-associated biological processes, such as proliferation, differentiation, apoptosis, metabolism, invasion, metastasis, and drug resistance in almost all cancer types, including BC [ 35 , 36 , 37 , 38 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer

Ruiz-Manriquez,

Villarreal-Garza,

Benavides-Aguilar

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide. Neoadjuvant therapy (NAT) is increasingly being used to reduce tumor burden prior to surgical resection. However, current techniques for assessing tumor response have significant limitations. Additionally, drug resistance is commonly observed, raising a need to identify biomarkers that can predict treatment sensitivity and survival outcomes. Circulating microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and have been shown to play a significant role in cancer progression as tumor inducers or suppressors. The expression of circulating miRNAs has been found to be significantly altered in breast cancer patients. Moreover, recent studies have suggested that circulating miRNAs can serve as non-invasive biomarkers for predicting response to NAT. Therefore, this review provides a brief overview of recent studies that have demonstrated the potential of circulating miRNAs as biomarkers for predicting the clinical response to NAT in BC patients. The findings of this review will strengthen future research on developing miRNA-based biomarkers and their translation into medical practice, which could significantly improve the clinical management of BC patients undergoing NAT.

show abstract

MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications

Cited by 20 publications

References 192 publications

Aging-associated long non-coding RNA boosts longevity and reduces the ribosome content of non-dividing fission yeast cells

Aging-associated long non-coding RNA boosts longevity and reduces the ribosome content of non-dividing fission yeast cells

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer

Contact Info

Product

Resources

About